Cocaine Dependence Clinical Trial
Official title:
Cocaine Withdrawal and Pharmacotherapy Response
A total of 120 male and female opioid dependent cocaine users will participate in this study. This study will be a 8-week double-blind, placebo controlled study examining the dose-dependent effects of carvedilol (up to 50 mg/day) in methadone stabilized patients. The design will have two phases: 1) a four-week "treatment " phase; and 2) a 4 week " taper and detoxification or transfer" phase. Subjects will be cocaine users who are on stable doses of methadone (60 to 140 mg/day). Carvedilol dose will be increased from 12.5mg/day to the target dose of either 25 or 50 mg/day as tolerated. At the end of the treatment-phase, subjects will undergo detoxification from methadone over a 2 to 4-week period based on an individual's needs, and they will concurrently be tapered off carvedilol.
The adrenergic neurotransmission serves multiple functions including learning, emotional processing and stress response to psychological and physical challenges (Huether, 1996; Sved et al., 2001). Adrenergic transmission also mediates drug withdrawal states and stress-induced relapse to drug use (Aston-Jones et al., 2004; Stewart, 2000). Consistent with these preclinical findings, adrenergic blockers showed promise as a treatment of cocaine dependence (Kampman et al., 2001b; Kampman et al., 2006). These preliminary findings are significant because there are no proven pharmacotherapies for cocaine addiction although an estimated 2.3 million of Americans aged 12 or older are regular cocaine users (SAMHSA, 2004). The societal cost of cocaine addiction is estimated to be $45 billion in the US, suggesting that development of even modestly effective cocaine pharmacotherapies will have great economic benefits. For example, availability of a medication decreasing cocaine use by 10 percent is estimated to have $745 million economic benefit in the US alone (Cartwright, 2000). Thus, developing effective treatments for cocaine addiction is an essential goal with significant benefits both for the society and the individual. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04994821 -
tDCS to Reduce Craving in Cocaine Addiction- Phase 2 Study
|
Phase 2 | |
Completed |
NCT01601743 -
Exercise as a Behavioral Treatment for Cocaine Dependence
|
N/A | |
Completed |
NCT01402492 -
Cocaine Use Reduction With Buprenorphine
|
Phase 2/Phase 3 | |
Completed |
NCT01176591 -
HBPL Study of the Impact of the NK1 Antagonist Aprepitant
|
Phase 2 | |
Completed |
NCT00880997 -
The Efficacy of Doxazosin for Cocaine Users
|
Phase 1 | |
Completed |
NCT00585520 -
Sex Differences in Progesterone Effects on Responses to Stress and Drug Cues
|
Phase 1 | |
Completed |
NCT00368290 -
Modafinil Treatment for Cocaine Dependence and HIV High-Risk Behavior
|
Phase 2 | |
Completed |
NCT00385801 -
Study of the Effects of Risperdal Consta on Brain Reward Circuitry Function, Craving and Cocaine Use in Active Cocaine Dependence
|
Phase 2 | |
Completed |
NCT00322309 -
Efficacy of Mirtazapine in Depressed Cocaine Dependent Subjects
|
Phase 2 | |
Completed |
NCT00842517 -
Long Term Maintenance of Drug Abstinence
|
Phase 1 | |
Completed |
NCT00167245 -
Topiramate for Alcohol and Cocaine Dependence
|
Phase 2 | |
Not yet recruiting |
NCT05974202 -
rTMS and Cognitive-behavioral Therapy for Cocaine Use Disorder
|
Phase 2 | |
Completed |
NCT04411914 -
Pharmaco-Magnetic Resonance Spectroscopy (MRS) Study of Clavulanic Acid
|
Phase 1 | |
Active, not recruiting |
NCT03266939 -
Rebalancing the Serotonergic System in Cocaine Dependence
|
Phase 1 | |
Completed |
NCT02563769 -
Clavulanic Acid (CLAV) and Cocaine Interaction Safety Study
|
Phase 1 | |
Recruiting |
NCT06159387 -
Randomized, Double-blind, Placebo-controlled Cannabis Extract x Placebo for Cocaine Addicts
|
Phase 4 | |
Terminated |
NCT02935101 -
Effects of Glucocorticoids on Craving During Detoxification Treatment of Heroin and/or Stimulants
|
Phase 2 | |
Completed |
NCT02018263 -
Validation of a Remote Wireless Sensor Network (WSN) Approach to the Individualized Detection of Cocaine Use in Humans
|
Phase 1 | |
Completed |
NCT01573273 -
Oxytocin in Cocaine Dependence
|
N/A | |
Withdrawn |
NCT01406522 -
Tacrine Effects on Cocaine Self-Administration and Pharmacokinetics
|
Phase 2 |